Senseera Raises $7.1M in Seed Funding
Summary
The round was led by Lightspeed Venture Partners, with participation from I-Next Capital and the Lowy Medical Research Institute. The company intends to use the funds to advance its GEM BIOMARKERS™ liquid biopsy platform, empowered by cfChIP-seq technology. Led by CEO Dr. Ronen Sadeh, Senseera provides a platform, GEM BIOMARKERS™, that helps drug development in cancer and immune disorders. By offering simultaneous solid tissue and immune cell states monitoring, the platform also provides insights into tissue/tumor immune cross-talk, enabling researchers and clinicians to better understand the underlying mechanisms and support personalized treatments.
Funding
Amount
$7.1M
Total raised
Date
January 7, 2025
Announcement date
Investors
-
Lead investors
Company
http://www.senseerahealth.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected